Will 14-3-3η Be a New Diagnostic and Prognostic Biomarker in Rheumatoid Arthritis? A Prospective Study of Its Utility in Early Diagnosis and Response to Treatment

• Published in: Autoimmune diseases Vol. 2022; pp. 1 - 8
• Main Authors: Alashkar, Doaa Shawky, Elkhouly, Radwa Mostafa, Abd Elnaby, Amira Yousef, Nada, Doaa Waseem
• Format: Journal Article
• Language: English
• Published: United States Hindawi 04.01.2022; John Wiley & Sons, Inc
• Subjects: Analysis; Antibodies; Arthritis; Biomarkers; Care and treatment; Disease; Enzyme-linked immunosorbent assay; Laboratories; Medical diagnosis; Medical prognosis; Patients; Peptides; Proteins; Rheumatism; Rheumatoid arthritis; Rheumatoid factor; Rheumatology; Serum levels; Therapeutic targets; Tumor necrosis factor; Tumor necrosis factor-TNF; Ultrasonic imaging; Illinois; Taiwan
• ISSN: 2090-0422; 2090-0430; 2090-0430
• DOI: 10.1155/2022/1497748

Aim of the Work. To evaluate diagnostic and prognostic capacity of 14-3-3η protein in early RA, investigate its pathogenic and theragnostic role, and find its correlations with disease activity and severity in established RA patients. Subjects and Methods: 80 patients with early RA, 80 patients with established RA, and 80 healthy controls were included in this study. ROC curve analysis of RF, ACCP, and 14-3-3η in early disease was conducted, and serum levels of 14-3-3η were assessed by ELISA and reassessed in early RA patients 6 months after anti-TNF therapy. Correlation of 14-3-3η with parameters of disease activity and severity was analyzed. Results. Serum14-3-3η levels were significantly higher in all RA patients than in controls P<0.001, its sensitivity was 86.7% and 88.3% in early and established RA patients with a significant difference with RF and ACCP at early disease, and the specificity was 96.7%. There was a significant reduction of 14-3-3η levels 6 months after treatment in the first group p=0.004, and there was a significant positive correlation between serum 14-3-3η levels and parameters of disease activity and severity. Conclusion. 14-3-3η could be a novel, potent, and efficacious diagnostic, and prognostic marker for RA with high sensitivity, that may become a new therapeutic target for RA.